Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-098340, an Investigational, Potent, Pan-Coronavirus 3CLPRO Inhibitor for Pandemic Preparedness

Tuesday, April 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses ALG-098340, an investigational drug designed to inhibit the 3CLPRO enzyme across various coronaviruses. This development is part of efforts to enhance pandemic preparedness. The drug's potential effectiveness against multiple strains highlights its significance in addressing future viral outbreaks.
Price reaction · baseline $6.43 (2026-04-27 close) · hit pre-market · 2 other ALGS headline(s) in the window, move may be shared
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of ALG-098340 as a potent inhibitor.
  • Focus on pandemic preparedness with pan-coronavirus capabilities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-098340?

ALG-098340 is an investigational drug designed to inhibit the 3CLPRO enzyme in coronaviruses.

How does ALG-098340 contribute to pandemic preparedness?

It aims to provide a therapeutic option against multiple coronavirus strains, enhancing readiness for future outbreaks.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-098340 pan-coronavirus 3CLPRO inhibitor pandemic preparedness
Last updated: Apr 28, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →